Tom (Tomasz M.) Beer, M.D.
News
Updates from the GU 2020
Atezolizumab and cabozantinib in mCRPC
Is PFS2 a legitimate endpoint?
TITAN study of apalutamide
OHSU News: Investigational blood test could detect many types of cancer with one blood draw - February 28, 2020
Portland Business Journal: OHSU chosen as site for early cancer detection study - February 18, 2020
KATU: OHSU looking for participants in cancer study - February 19, 2020
KPTV: Doctors at OHSU working on blood test for early cancer detection- February 19, 2020
KEX: OHSU Studying Cancer Blood Test- February 19, 2020
Arvinas Strengthens Scientific Advisory Board with Leaders in Oncology and Neurological Disorders - October 2, 2019
Editor Comments on OBR Daily I regularly comment on developments in prostate cancer
What Do Today’s Valuations Mean for Investors? Blog post on the White Coat Investor - April 10, 2019
Plenary Session Podcast Personal Finance for Physicians
Updates from the GU 2019
Plenary Session Podcast I am interviewed by Dr. Vinay Prasad on philanthropy and cancer research. Interview segment starts at the 12th minute
OHSU Opens New Cancer Center - Jefferson Public Radio Interview - November 7, 2018
Story Introduction
Audio Stream
The Link Between Apalutamide and QOL in Non-Metastatic CRPC - Cancer Network October 9, 2018
On importance of cancer research KPTV - September 8, 2018
Advances in Imaging, Therapies Bode Well for nmCRPC Management - Renal and Urology News, August 31, 2018
Prostate cancer screening: Middle ground may be reachable with latest recommendations—The Scribe. Ju
Updates from the ASCO 2018 Annual Meeting
OHSU Opens New Cancer Center - Jefferson Public Radio Interview - November 7, 2018
Story Introduction
Audio Stream
The Link Between Apalutamide and QOL in Non-Metastatic CRPC - Cancer Network October 9, 2018
On importance of cancer research KPTV - September 8, 2018
Advances in Imaging, Therapies Bode Well for nmCRPC Management - Renal and Urology News, August 31, 2018
Prostate cancer screening: Middle ground may be reachable with latest recommendations—The Scribe. Ju
Updates from the ASCO 2018 Annual Meeting
Immunotherapy in CRPC
PROSPER and SPARTAN studies
Multimodality treatment
Central themes at ASCO 2018
Under- and over-diagnosis
Buehler...? Buehler...? Buehler?—Oregon Business Magazine. February 28, 2018.
The $1B question: Can OHSU Really Cure Cancer?—OPB. October 11, 2017.
Can a Building Help Cure Cancer?—OPB. October 11, 2017.
Did he really just tweet that? Dr. Vinay Prasad takes on Big Pharma, Big Medicine, and his own colleagues — with glee—STAT. September 15, 2017.
Should oncologists recommend hormone therapy plus abiraterone for patients with nonmetastatic prostate cancer?—HemOnc Today. September 10, 2017.
Dr. Vinay Prasad, OHSU's iconoclastic oncologist, calls out shoddy medicine—The Oregonian. September 7, 2017.
A taxpayer gamble on medical tourism: Louisiana subsidizes proton therapy to boost its economy—STAT. June 2, 2017.
The $1B question: Can OHSU Really Cure Cancer?—OPB. October 11, 2017.
Can a Building Help Cure Cancer?—OPB. October 11, 2017.
Did he really just tweet that? Dr. Vinay Prasad takes on Big Pharma, Big Medicine, and his own colleagues — with glee—STAT. September 15, 2017.
Should oncologists recommend hormone therapy plus abiraterone for patients with nonmetastatic prostate cancer?—HemOnc Today. September 10, 2017.
Dr. Vinay Prasad, OHSU's iconoclastic oncologist, calls out shoddy medicine—The Oregonian. September 7, 2017.
A taxpayer gamble on medical tourism: Louisiana subsidizes proton therapy to boost its economy—STAT. June 2, 2017.